SOLIQUA 100/33
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOLIQUA 100/33 (SOLIQUA 100/33).
SOLIQUA 100/33 is a fixed-ratio combination of insulin glargine and lixisenatide. Insulin glargine is a long-acting basal insulin analog that binds to insulin receptors, promoting cellular glucose uptake and inhibiting hepatic gluconeogenesis. Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that potentiates glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying.
| Metabolism | Insulin glargine: Metabolized via degradation pathways producing metabolites with minimal activity. Lixisenatide: Primarily metabolized by proteolysis and peptidases, with minimal renal excretion of intact drug. |
| Excretion | Renal: ~30% unchanged; biliary/fecal: ~70% as metabolites. |
| Half-life | Lixisenatide: ~3 hours; insulin glargine: ~12-24 hours (depot). |
| Protein binding | Lixisenatide: ~55%; insulin glargine: ~30% (albumin). |
| Volume of Distribution | Lixisenatide: ~100 L; insulin glargine: ~0.7 L/kg. |
| Bioavailability | Subcutaneous: ~90% for lixisenatide; ~80% for insulin glargine. |
| Onset of Action | Subcutaneous: lixisenatide ~1-2 hours; insulin glargine ~1-2 hours (slow). |
| Duration of Action | Lixisenatide: ~5-6 hours; insulin glargine: up to 24 hours. |
Subcutaneous injection once daily, initial dose 15 units (insulin glargine equivalent) for patients not previously treated with insulin, with 1 unit per 10g carbohydrate or per 15-30 mg/dL blood glucose elevation.
| Dosage form | SOLUTION |
| Renal impairment | eGFR 30-59 mL/min: monitor glucose closely, reduce dose by 20-30%. eGFR 15-29 mL/min: reduce dose by 30-50%. eGFR <15 mL/min: avoid use or use with extreme caution. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric use; no established weight-based dosing. |
| Geriatric use | Initiate at lower dose (e.g., 15 units) and titrate slowly; monitor for hypoglycemia and renal function; consider reducing dose by 20% if eGFR <60 mL/min. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SOLIQUA 100/33 (SOLIQUA 100/33).
| Breastfeeding | Insulin glargine is excreted in breast milk in low amounts; lixisenatide is not known. M/P ratio not available. Caution advised; monitor infant for hypoglycemia. |
| Teratogenic Risk | First trimester: Insulin glargine and lixisenatide do not cross the placenta significantly; however, data are limited. No increased risk of major malformations reported. Second and third trimesters: Poorly controlled diabetes increases risk of fetal macrosomia, hypoglycemia, and neonatal respiratory distress. Lixisenatide may cause fetal harm in animal studies (reduced fetal weight, skeletal ossification delays). Avoid use in pregnancy unless benefit outweighs risk. |
■ FDA Black Box Warning
WARNING: RISK OF THYROID C-CELL TUMORS. Lixisenatide causes thyroid C-cell tumors in rodents. It is unknown whether SOLIQUA 100/33 causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. SOLIQUA 100/33 is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
| Serious Effects |
["Hypersensitivity to insulin glargine, lixisenatide, or any excipients","Personal or family history of medullary thyroid carcinoma (MTC)","Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)","During episodes of hypoglycemia"]
| Precautions | ["Thyroid C-cell tumor risk","Acute pancreatitis","Hypoglycemia","Hypersensitivity reactions","Renal impairment","Gastrointestinal effects","Immunogenicity","Macrovascular outcomes: No conclusive evidence"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose, HbA1c, and weight gain. Fetal surveillance: ultrasound for growth, amniotic fluid volume; nonstress test or biophysical profile in third trimester if diabetic complications. |
| Fertility Effects | No known direct effects on fertility. Improved glycemic control may improve fertility in diabetic women. |